UBS Group Initiates Coverage on Icade (OTCMKTS:CDMGF)

UBS Group initiated coverage on shares of Icade (OTCMKTS:CDMGF) in a report released on Friday morning, The Fly reports. The brokerage issued a buy rating on the stock.

A number of other equities analysts have also recently commented on the stock. Societe Generale began coverage on shares of Icade in a research note on Tuesday, November 23rd. They issued a buy rating for the company. Morgan Stanley dropped their price target on shares of Icade from €85.00 ($96.59) to €78.00 ($88.64) in a research note on Wednesday, January 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Icade has an average rating of Buy and an average price target of $83.09.

Shares of OTCMKTS:CDMGF opened at $75.15 on Friday. Icade has a 52 week low of $68.41 and a 52 week high of $92.93. The firm has a fifty day simple moving average of $73.97 and a two-hundred day simple moving average of $81.14.

Icade Company Profile

As an investor and a developer, Icade is an integrated real estate player that designs innovative real estate products and services adapted to new urban lifestyles and habits. By placing corporate social responsibility and innovation at the core of its strategy, Icade is closely involved with stakeholders and users in the citiesÂlocal authorities and communities, companies and employees, institutions and associations As an office and healthcare property investor (portfolio value of Â11.6bn as of 06/30/2020 on a proportionate consolidation basis) and as a property developer (2019 economic revenues of nearly Â1bn), Icade has been able to reinvent the real estate business and foster the emergence of tomorrow's greener, smarter and more responsible cities.

See Also: What is the 52-week high/low?

The Fly logo

Analyst Recommendations for Icade (OTCMKTS:CDMGF)

Receive News & Ratings for Icade Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icade and related companies with MarketBeat.com's FREE daily email newsletter.